Two adult patients with severe immune neutropenia refractory to standard therapies achieved durable remission following treatment with the JAK inhibitor ruxolitinib. This report highlights the potential of JAK–STAT pathway inhibition for managing G-CSF and steroid-refractory immune-mediated neutropenia.
5 November 2025 in Clinical Lymphoma Myeloma and Leukemia
1. Castleman disease (CD) is a rare disease characterized by lymphadenopathy and a wide range of clinical manifestations ranging from focal lymphadenopathy to diffuse lymphoproliferation, systemic ...